AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 29 Sept, 12:49 UTC

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

science

Sources

• T2AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug pushBioPharma Dive / Healthcare Dive / MedTech Dive29 Sept, 12:49